The main objective of the study is to determine if intrarticular injection with liposomal
bupivicaine (Exparel) provides better postoperative pain relief and functional outcome
following total knee replacement (TKR) than the current standard New England Baptist
Hospital regimen of femoral nerve block combined with intraarticular injection of a standard
A prospective, single blind study comparing femoral nerve blockade and intraarticular
posterior capsular injection to interarticular injection of bupivicaine and liposomal
bupivicaine (Exparel) alone.
• Patients between the ages of 18 - 73 who are undergoing primary, unilateral, Total Knee
Replacement at the New England Baptist Hospital in Boston, Massachusetts are eligible to
- Patients with Revision or Complex Total Knee Replacements and are under the age of
18, or over the age of 73 will be excluded.
- Patients with an ASA 4 level will be excluded.
- Patients with a Body Mass Index of less than 20, and over 40, will be excluded.
- Patients taking preoperative narcotics, patients with extreme sensitivity or allergy
to narcotics or local anesthetics, and patients using opioid medications for at least
3 months leading up to surgery, will also be excluded.